This announcement is a separate document:
亞盛醫藥-B：自願公告 - 亞盛醫藥獲得美國FDA的許可，將開展奧雷巴替尼針對過往接受過治療的慢性髓細胞白血病慢性期(CML-CP)患者的全球註冊3期臨床試驗
ASCENTAGE-B: Voluntary Announcement - Ascentage Pharma Received Clearance from U.S. FDA to Initiate Global Registrational Phase 3 Clinical Trial for Olverembatinib in Previously Treated Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.